Clinical Trial: Expanded Access Study Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS), Congenital Myasthenic Syndrome (CMS), or Downbeat Nystagmus Patients

Study Status: Available
Recruit Status: Available
Study Type: Expanded Access

Official Title: An Open-Label, Expanded Access Protocol for Amifampridine Phosphate Treatment in Patients With Lambert-Eaton Myasthenic Syndrome (LEMS), Congenital Myasthenic Syndrome (CM

Brief Summary:

The primary objective of the study is:

• To provide patients with LEMS/CMS/downbeat nystagmus access to amifampridine phosphate therapy until the product becomes commercially available.

The secondary objective of the study is:

• To assess the long-term safety of amifampridine phosphate in patients with LEMS/CMS/downbeat nystagmus

Detailed Summary:
Sponsor: Catalyst Pharmaceuticals, Inc.

Current Primary Outcome:

Original Primary Outcome:

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Catalyst Pharmaceuticals, Inc.

Dates:
Date Received: July 5, 2014
Date Started:
Date Completion:
Last Updated: January 31, 2017
Last Verified: January 2017